shares drug suspension
shares elan biogen idec plunged firms suspended sales multiple sclerosis drug tysabri patient death
stock exchange shares elan partner biogen idec firms death nervous disease suspected condition cited tysabri avonex biogen idec multiple sclerosis drug rare condition progressive multifocal leukoencephalopathy pml patients tysabri avonex tysabri approved tipped multiple sclerosis treatment
clinical investigators evaluate patients consult experts understand pml firms outcome evaluations determine dosing clinical trials commercial availability
analysts product opportunity biogen idec faced competition rivals avonex elan irish stock exchange product inquiry elan accounts bankruptcy rebuilding price increasing tysabri ian hunter goodbody stockbrokers dublin question elan finished biogen fell
shares pharmaceutical phytopharm closed pence stock exchange partner pull experimental alzheimer disease treatment phytopharm japan yamanouchi pharmaceutical licensing prompting analysts questions reserves
